News & Updates

Adding lenzilumab, a monoclonal antibody targeting GM-CSF, on top of standard supportive care significantly improves survival without the need of invasive mechanical ventilation at 28 days in patients hospitalized with COVID-19 compared with standard care alone, reveals the LIVE-AIR study.

The combination of mesalamine plus corticosteroid does not appear to be more beneficial than corticosteroid alone in the treatment of hospitalized patients with acute severe ulcerative colitis (UC), as shown in a study.

Moroctocog alfa Powder for injection

Insulin glargine Solution for injection

Adalimumab Solution for injection

Semaglutide Tablet

Osimertinib Film-coated tablet